Back to Top Skip to main content

Defending the Homeland: Turning on lifesaving trials at Madigan Army Medical Center

Image of soldier in front of a laptop Janell Cain, a clinical research coordinator at Madigan with the Infectious Disease Clinical Research Program, records the informed consent forms signed by a patient receiving treatment for COVID-19 in the intensive care unit from Madigan’s Virtual Critical Care Center on April 14. Communicating with the patient and nurses via the video equipment, Cain gains the necessary consent to enroll a patient in a study of remdesivir as a COVID-19 treatment without expending personal protective equipment, or exposing anyone to the patient unnecessarily. The IDCRP is a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. (Lt. Col. (Dr.) Christopher Colombo)

Recommended Content:

Coronavirus

MADIGAN ARMY MEDICAL CENTER, Joint Base Lewis-McChord, Wash. – Madigan Army Medical Center, on Joint Base Lewis-McChord, Wash., has been a hotbed for biomedical research for years, highlighted by patented innovations and award winning presentations at national and international scientific meetings.

In response to the COVID-19 global pandemic, Madigan is currently supporting nine research protocols designed to address gaps in knowledge including clinical characteristics of the COVID-19 illness, the impact of nutrition on COVID-19 risk, and the clinical value of convalescent plasma, in which a patient with severe disease is given plasma from someone who has recovered from COVID-19 and therefore has antibodies to it in their blood, to name a few.

Possibly the most notable clinical trial for COVID-19 treatment involves remdesivir, an investigational, broad-spectrum antiviral drug that has shown some promise, in animal trials, in both Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses.

The trial is sponsored by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, and is the first clinical trial in the U.S. to evaluate an experimental treatment for COVID-19.

When the trial began in February, Dr. Anthony Fauci, the director of NIAID and a member of the U.S. Coronavirus Task Force said, “We urgently need a safe and effective treatment for COVID-19. Although remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes. A randomized, placebo-controlled trial is the gold standard for determining if an experimental treatment can benefit patients.”

Madigan is one of 68 international trial sites among 47 in the U.S. and 21 in Europe and Asia. The first enrollee was at the University of Nebraska Medical Center/Nebraska Medicine, in February; he had been on a cruise ship that saw a number of infections.

The initiation of the trial can is described here: https://www.niaid.nih.gov/news-events/nih-clinical-trial-remdesivir-treat-covid-19-begins.

Within two months of initiation, the clinical trial of remdesivir has produced encouraging results.

In a statement issued on April 29, the NIAID reported, “Preliminary results indicate that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0 percent for the group receiving remdesivir versus 11.6 percent for the placebo group (p=0.059).”

This trial is managed at Madigan by the Infectious Disease Clinical Research Program, a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. The IDCRP conducts clinical research that focuses on reducing the impact of infectious diseases relevant to the DoD.

For more information about the IDCRP, visit: https://www.idcrp.org/about-us.

The IDCRP has a broad research portfolio, including an ongoing study looking at the efficacy of different formulations of the flu vaccine. When COVID-19 emerged, the IDCRP pivoted to get this research up and running in a very short period of time. As an established IDCRP site, Madigan was identified as one of the military treatment facilities eligible for participation in the NIAID trial.

“Because they are so active and such a squared-away group, they were able to help get this trial off the ground,” said Lt. Col. (Dr.) Christopher Colombo, principal investigator for the COVID-19 trial and the director of Virtual Health and Telecritical Care at Madigan.

Madigan has strong and adaptive biomedical research capabilities that are facilitated by its Department of Clinical Investigation.

“The Department of Clinical Investigation, Dr. Rick Burney (DCI’s chief) and Dr. (Silvija) Salai (the human subject protection administrator), have been fantastic in supporting and expediting this and balancing making sure that everything is still done dress-right-dress according to regulatory, safety and scientific integrity filings, but it is going quite a bit faster than usual, because of the situation that we're in,” noted Lt. Col. Colombo.

Madigan is one of five DoD sites that has enrolled patients in the study so far and is already ramping up for its next phase. Investigators stress that these are early days of evaluation for this trial. Given the high transmissibility and global spread of this virus, research has moved quickly.

“It's a placebo controlled trial, so the patients are randomized. We don't know who's getting what. They either get placebo or remdesivir,” Lt. Col. Colombo said.

NIH requirements for inclusion in the trial comprise the need for hospitalization for documented COVID-19 infection and either an abnormal chest x-ray or the requirement for supplemental oxygen or mechanical ventilation. Trial participation is limited to adults.

Participants in the treatment group get 200 milligrams (mg) of remdesivir injected on the first day they are in the study and 100 mg each day of their hospitalization, up to 10 days total. Those in the placebo group receive the same amount of what looks like remdesivir but contains only inactive ingredients.

This means the trial is administered to patients currently being treated in the hospital, though some have since improved and gone home. They return to the hospital periodically for monitoring.

Dr. Rhonda Colombo, an infectious diseases physician who works in support of the IDCRP at Madigan, praised the contributions of patients who volunteered to participate in this and other ongoing clinical research trials.

“Without willing and engaged study participants, clinical research is not possible. At Madigan, we are incredibly fortunate to be part of a community that values clinical research. Our research team is humbled by the generosity and commitment of the people who volunteer to participate in our studies,” said Dr. Colombo.

With drug safety and long-term effects always in mind, the team is not yet ready to draw conclusions, but is optimistic about the data so far.

Susan Chambers, the clinical operations manager for the IDCRP at Madigan echoed that appreciation for the high value that Madigan, and the JBLM community place on research, noting that it is the providers and nurses on the inpatient units who directly support research within their care of patients.

“We are incredibly proud to have the opportunity to offer access to cutting-edge research for our Active Duty personnel and DoD beneficiaries. Our success would not be possible without the support of Madigan Commander Col. Thomas Bundt and the committed inpatient clinical care teams at Madigan,” said Chambers.

On Friday, May 1, the U.S. Food and Drug Administration gave remdesivir emergency use authorization to treat COVID-19.

The NIAID expects to share additional data soon, as well as next steps.

“We managed to get meaningful research turned on, very quickly. Other sites in the Department of Defense, are kind of looking at Madigan like you guys are knocking it out of the park, keep going,” said Lt. Col. Colombo. “I think it's something that's cool in terms of how we're responding to COVID in a positive way and making some good come of this.”

Disclaimer: Re-published content may be edited for length and clarity.  Read original post.

You also may be interested in...

Got Your 6: Step Up

Video
3/18/2021
Got Your 6: Step Up

“Got Your 6” is TRICARE’s COVID-19 vaccine video series that delivers important information and updates, three times a month. It includes the latest information about DoD vaccine distribution, the TRICARE health benefit, and vaccine availability for a DoD-affiliated, and TRICARE beneficiary audience.

Recommended Content:

COVID-19 Toolkit | Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

TRICARE | COVID-19 Vaccine | Together, We Are Stronger

Video
3/15/2021
DHA Seal

In the past year, we've faced challenges, and we've done it with courage. Now, hope is on the horizon. Get vaccinated, and let's take care of each other. Together, we are stronger: www.tricare.mil/CovidVaccine

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus | COVID-19 Vaccine Toolkit

Secretary of Defense Video to the Force on COVID-19 Vaccinations

Video
2/24/2021
Image of soldier looking through COVID vaccine information laid out on a table

The Secretary of Defense addressed the entire workforce to encourage informed decision-making with regards to coronavirus-19 vaccination.

Recommended Content:

COVID-19 Toolkit | Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

MHS Minute: A Path Forward in 2021

Video
2/10/2021
DHA Seal

Want to know more about what MHS organizations and partners did in 2020? For a full look at the MHS Minute series, click here: https://shorturl.at/eDL14

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

LTG Place Vaccine Roll-Out Video

Video
1/18/2021
DHA Seal

DHA Director LTG Ron Place talks about coronavirus vaccines, their safety and efficacy, and encourages everyone to do their own research to get vaccinated.

Recommended Content:

COVID-19 Toolkit | Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

MHS Minute: December 2020

Video
12/28/2020
DHA Seal

See how MHS is leading a phased approach to offer 11.1 million Department of Defense personnel the first COVID-19 vaccines. To learn more about the safety and efficacy behind COVID-19 vaccines, go to: https://www.health.mil/Military-Health-Topics/Combat-Support/Public-Health/Coronavirus/COVID-19-Vaccine-Efforts.

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus

MHS COVID Response

Video
12/21/2020
DHA Seal

The men and women of the Military Health System spent 2020 working to protect beneficiaries' health during the coronavirus pandemic. Here are just a few of our accomplishments.

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts

Heroes Behind the Mask

Video
12/17/2020
DHA Seal

A tribute to those across the Military Health System who deserve recognition and thanks for their hard work during this pandemic.

Recommended Content:

Coronavirus | Heroes Behind the Mask | Heroes Behind the Mask

COVID-19 Response

Video
11/27/2020
DHA Seal

Army Pfc. David Alvarado, assigned to the Javits New York Medical Station (JNYMS), talks about their position at JNYMS in support of the Department of Defense COVID-19 response, April 24, 2020. U.S. Northern Command, through U.S. Army North, is providing military support to the Federal Emergency Management Agency to help communities in need. (U.S. Army Video by Cpl. Rachel Thicklin.)

Recommended Content:

Coronavirus | Heroes Behind the Mask

COVID-19 Response2

Video
11/27/2020
DHA Seal

Army Spc. Sean Colangelo, assigned to the Javits New York Medical Station (JNYMS), talks about their position at JNYMS in support of the Department of Defense COVID-19 response, April 23, 2020. U.S. Northern Command, through U.S. Army North, is providing military support to the Federal Emergency Management Agency to help communities in need. (U.S. Army Video by Cpl. Rachel Thicklin)

Recommended Content:

Coronavirus | Heroes Behind the Mask

How Can Vaccine and Antibody Studies Move So Quickly and Still Be Safe?

Video
11/3/2020
How Can Vaccine and Antibody Studies Move So Quickly and Still Be Safe?

This video provides a detailed overview of the processes that have been implemented to accelerate the pace of the COVID-19 vaccine and antibody studies, and what is being done to assure safety.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

The Importance of Enrolling Diverse Participants in COVID-19 Studies

Video
11/3/2020
The Importance of Enrolling Diverse Participants in COVID-19 Studies

This video discusses why enrolling diverse participants in COVID-19 studies is critical for ensuring that, when we find a vaccine, we have enough data from populations who are most affected by COVID-19 to determine vaccine safety and efficacy.

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus

MHS Minute: Heroes Behind the Mask

Video
10/8/2020
Image of MHS Minute Carousel

In the face of a global threat, healthcare heroes across the MHS have donned their mask, and served on the front line of the battle against COVID-19. Tune in to this month's "MHS Minute" to learn more!

Recommended Content:

Coronavirus | Heroes Behind the Mask

The Military Health System Celebrates Labor Day

Video
9/4/2020
The Military Health System Celebrates Labor Day

Labor Day pays tribute to the American workforce. This year, we pay tribute to the Military Health System Workforce.

Recommended Content:

Coronavirus

MHS Minute: A Call to Action for Convalescent Plasma Donation

Video
8/24/2020
Image of MHS Minute Carousel

Have you recovered from COVID-19, or tested positive for antibodies? Consider donating convalescent plasma. For eligibility requirements, and to find a donor center near you, go to https://www.militaryblood.dod.mil/Donors/COVID-19andBloodDonation.aspx

Recommended Content:

Coronavirus | Convalescent Plasma Collection Program | Armed Services Blood Program
<< < 1 2 3 > >> 
Showing results 1 - 15 Page 1 of 3

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.